阿替普酶联合阿加曲班治疗急性脑梗死临床效果及预后分析

Clinical Effect and Prognosis Analysis of Alteplase Combined with Argatroban in the Treatment of Acute Cerebral Infarction

目的分析阿替普酶联合阿加曲班治疗急性脑梗死临床效果及预后分析。方法选择该院2016年1月-2019年1月收治120例急性脑梗死患者临床资料,按随机数表分两组,对照组60例使用阿替普酶治疗,研究组60例在对照组基础上添加阿加曲班治疗,对比两组患者临床疗效及不良反应情况。结果治疗后,研究组痊愈27例,显效17例,研究组患者临床总有效95.00%比对照组高81.66%,差异有统计学意义(χ^2=5.175 2,P<0.05);且治疗前,两组患者NIHSS、Barthel评分,差异无统计学意义(P>0.05);研究组治疗后NIHSS(9.88±2.97)分、Barthel(37.51±8.67)分比对照组低,差异有统计学意义(t=4.879 7、7.515 5,P<0.05);研究组不良反应发生率8.33%比对照组21.66%低,差异有统计学意义(χ^2=4.183 0,P<0.05)。结论急性脑梗死患者使用阿替普酶联合阿加曲班治疗,可改善患者神经缺损程度,减少不良反应发生,有效提高患者临床疗效,临床上值得推广使用。

Objective To analyze the clinical effect and prognosis of alteplase combined with argatroban in the treatment of acute cerebral infarction. Methods The clinical data of 120 patients with acute cerebral infarction admitted to our hospital from January 2016 to January 2019 were divided into two groups according to the random number table. 60 patients in the control group were treated with alteplase, and 60 patients in the study group were on the basis of the control group, adding argatroban, the clinical efficacy and adverse reactions of the two groups were compared. Results After treatment, the study group recovered 27 cases and markedly effective 17 cases. The clinical total effective 95.00% of the study group was 81.66% higher than the control group, the difference was statistically significant (χ^2=5.175 2,P<0.05);and before treatment, the two groups had no significant differences in NIHSS and Barthel scores between the patients. The difference was not statistically significant. The NIHSS (9.88±2.97)points and Barthel (37.51±8.67) points were lower in the study group than in the control group, and the difference was statistically significant (t=4.879 7,7.515 5,P<0.05);The incidence of adverse reactions in the study group was 8.33% lower than that in the control group of 21.66%, and the difference was statistically significant (χ^2=4.183 0,P<0.05). Conclusion Alteplase combined with argatroban in patients with acute cerebral infarction can improve the degree of neurological deficit, reduce the incidence of adverse reactions, and effectively improve the clinical efficacy of patients. It is worthy of popularization.